MODIFICACION CRISTALINA DE N-ETIL-2,2-DICLORO-1-METILCICLOPROPANO-CARBOXAMIDA-2(2,6-DICLORO-ALFA,ALFA,ALFA-TRIFLOURO-p-TOTIL)HIDRAZONA

    公开(公告)号:PE20070799A1

    公开(公告)日:2007-09-28

    申请号:PE2006001344

    申请日:2006-11-02

    Applicant: BASF AG

    Inventor: ZIERKE THOMAS

    Abstract: SE REFIERE A UNA MODIFICACION CRISTALINA I DE N-ETIL-2,2-DICLORO-1-METILCICLOPROPANO-CARBOX-AMIDA-2-(2,6-DICLORO-a,a,a-TRIFLUORO-p-TOLIL)HIDRAZONA (COMPUESTO I) QUE ESTA PRESENTE EN UN SISTEMA TRICLINICO Y TIENE EL GRUPO ESPACIAL P-1, EL CUAL EN UN DIAFRACTOGRAMA DE RAYOS X EN POLVO A 25ºC, EXHIBE LAS REFLEXIONES SIGUIENTES: d = 17,1 ± 0.5Å; 11,5± 0.2Å; 9,9 ± 0.2Å; 8,9 ± 0.2Å; 7,35 ± 0.05Å, ENTRE OTROS, Y TIENE UN PUNTO DE FUSION EN EL INTERVALO 76,0 A 80,5ºC. UN PROCESO DE PREPARACION QUE COMPRENDE EN i)PREPARAR UNA SOLUCION DEL COMPUESTO I AMORFO EN UN DISOLVENTE ORGANICO TAL COMO METANOL O ISOPROPANOL O UNA MEZCLA DE ESTOS, Y OPCIONALMENTE DISOLVENTES ADICIONALES; ii) EFECTUAR LA CRISTALIZACION Y iii) AISLAR EL PRECIPITADO. TAMBIEN SE REFIERE A UNA COMPOSICION UTIL PARA COMBATIR PLAGAS Y PARASITOS

    MODIFICACION CRISTALINA DE N-ETIL-2,2-DICLORO-1-METILCICLOPROPANO-CARBOXAMIDA-2(2,6-DICLORO-ALFA,ALFA,ALFA-TRIFLOURO-p-TOTIL)HIDRAZONA

    公开(公告)号:PE07992007A1

    公开(公告)日:2007-09-28

    申请号:PE0013442006

    申请日:2006-11-02

    Applicant: BASF AG

    Inventor: ZIERKE THOMAS

    CPC classification number: A01N53/00 C07C257/22 C07C2601/02

    Abstract: SE REFIERE A UNA MODIFICACION CRISTALINA I DE N-ETIL-2,2-DICLORO-1-METILCICLOPROPANO-CARBOX-AMIDA-2-(2,6-DICLORO-a,a,a-TRIFLUORO-p-TOLIL)HIDRAZONA (COMPUESTO I) QUE ESTA PRESENTE EN UN SISTEMA TRICLINICO Y TIENE EL GRUPO ESPACIAL P-1, EL CUAL EN UN DIAFRACTOGRAMA DE RAYOS X EN POLVO A 25ºC, EXHIBE LAS REFLEXIONES SIGUIENTES: d = 17,1 ± 0.5Å; 11,5± 0.2Å; 9,9 ± 0.2Å; 8,9 ± 0.2Å; 7,35 ± 0.05Å, ENTRE OTROS, Y TIENE UN PUNTO DE FUSION EN EL INTERVALO 76,0 A 80,5ºC. UN PROCESO DE PREPARACION QUE COMPRENDE EN i)PREPARAR UNA SOLUCION DEL COMPUESTO I AMORFO EN UN DISOLVENTE ORGANICO TAL COMO METANOL O ISOPROPANOL O UNA MEZCLA DE ESTOS, Y OPCIONALMENTE DISOLVENTES ADICIONALES; ii) EFECTUAR LA CRISTALIZACION Y iii) AISLAR EL PRECIPITADO. TAMBIEN SE REFIERE A UNA COMPOSICION UTIL PARA COMBATIR PLAGAS Y PARASITOS

    55.
    发明专利
    未知

    公开(公告)号:BRPI0508602A

    公开(公告)日:2007-07-31

    申请号:BRPI0508602

    申请日:2005-03-16

    Applicant: BASF AG

    Abstract: The invention relates to a process for preparing semicarbazone compounds of the formula I, where R1 and R2 are each independently hydrogen, halogen, CN, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-haloalkyl or C1-C4-haloalkoxy, and R3 is C1-C4-alkoxy, C1-C4-haloalkyl or C1-C4-haloalkoxy, by reacting a hydrazone compound of the general formula II, where R is C1-C4-alkoxy, amino, C1-C4-alkylamino or di(C1-C4-alkyl)amino, and R1, R2 are each as defined above, with an aniline compound of the general formula III where R3 is as defined above.

    DOLASTATINE 15 DERIVATIVES
    56.
    发明专利

    公开(公告)号:BG65212B1

    公开(公告)日:2007-07-31

    申请号:BG10408900

    申请日:2000-01-17

    Applicant: BASF AG

    Abstract: The invention relates to inhibitors of the cellular growth and to their adjunctive to acid salts which are peptides with the formula A - B - D - E - F - (G)r - (K)s - L (I) where A, B, D, E, F, G. and K are -aminoacid residues and s and r are, individually, 0 or 1. L is univalent radical, such as aminogroup, N-substituted aminogroup, beta-hydroxyaminogroup, beta-hydroxyaminogroup, hydrasidogroup, alkoxygroup, thioalkoxygroup, aminooxygroup or oximatogroup. The invention also relates to a method for the treatment of cancer in mammals, including humans which includes the administration of an effective quantity of the above compound in a pharmaceutically acceptable composition.

    Dolastatin 15 derivatives
    60.
    发明专利

    公开(公告)号:AU750120B2

    公开(公告)日:2002-07-11

    申请号:AU8475898

    申请日:1998-07-07

    Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L  (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

Patent Agency Ranking